Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1074/jbc.M114.603464

http://scihub22266oqcxt.onion/10.1074/jbc.M114.603464
suck pdf from google scholar
C4246088!4246088 !25315772
unlimited free pdf from europmc25315772
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid25315772
      J+Biol+Chem 2014 ; 289 (48 ): 33311-9
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack #MMPMID25315772
  • Wang W ; Guo H ; Geng J ; Zheng X ; Wei H ; Sun R ; Tian Z
  • J Biol Chem 2014[Nov]; 289 (48 ): 33311-9 PMID25315772 show ga
  • Human Galectin-3 (Gal-3), a ?-galactoside-binding protein expressed by tumor cells, has been reported to act as an immune regulator in antitumor T cells. However, its effect on natural killer (NK) cells is elusive. Using a recombinant human NK cell-activating receptor, NKp30 fusion protein (NKp30-Fc), we found that soluble NKp30-Fc could immunoprecipitate Galectin-3. The direct interaction between NKp30 and Galectin-3 was further confirmed using surface plasmon resonance experiments. Because Galectin-3 was mainly released from tumor cells in a soluble form in our study, the binding assay was performed to show that soluble Galectin-3 specifically bound to NK cells and NKp30 on the surface of the NK cells. Functionally, when soluble Galectin-3 was added to the NK-tumor cell coculture system, the NKp30-mediated, but not NKG2D-mediated, cytolysis and CD107a expression in the NK cells were inhibited, and these phenotypes could be restored by preincubation of soluble Galectin-3 with NKp30-Fc fusion protein or the addition of anti-Gal-3 antibody alone. Moreover, genetic down-regulation of Galectin-3 (shGal-3) resulted in tumor cells being more sensitive to NK cell lysis, and, reversely, Galectin-3-overexpressing HeLa cells (exGal-3) became less sensitive to NK cell killing. The results of these in vitro experiments were supported by studies in shGal-3-HeLa or exGal-3-HeLa xenograft non-obese diabetic/severe combined immunodeficiency mice after NK cell adoptive immunotherapy, indicating that Galectin-3 strongly antagonizes human NK cell attack against tumors in vivo. These findings indicate that Galectin-3 may function as an immune regulator to inhibit NK cell function against tumors, therefore providing a new therapeutic target for tumor treatment.
  • |*Immunity, Cellular [MESH]
  • |*Tumor Escape [MESH]
  • |Animals [MESH]
  • |Blood Proteins [MESH]
  • |Down-Regulation/genetics/immunology [MESH]
  • |Galectin 3/genetics/*immunology [MESH]
  • |Galectins [MESH]
  • |Gene Expression Regulation, Neoplastic/genetics/immunology [MESH]
  • |HeLa Cells [MESH]
  • |Heterografts [MESH]
  • |Humans [MESH]
  • |Lysosomal-Associated Membrane Protein 1/genetics/immunology [MESH]
  • |Mice [MESH]
  • |Mice, Inbred NOD [MESH]
  • |Mice, SCID [MESH]
  • |NK Cell Lectin-Like Receptor Subfamily K/genetics/immunology [MESH]
  • |Natural Cytotoxicity Triggering Receptor 3/genetics/*immunology [MESH]
  • |Neoplasm Proteins/genetics/*immunology [MESH]
  • |Neoplasm Transplantation [MESH]
  • |Neoplasms/genetics/*immunology [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box